Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.40 |
| ▸ | MARS1 | P56192 | 1/20 | 0.37 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.36 |
| ▸ | IL15 | P40933 | 3/20 | 0.35 |
| ▸ | IL15RA | Q13261 | 2/20 | 0.35 |
| ▸ | IL2 | P60568 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844049 | 0.89 | CRHR1 (0.41) | CRHR1CNKSR1IL15IL15RAIL2 | |
| SCHEMBL3843569 | 0.89 | CRHR1 (0.44) | CRHR1HSD11B1 | |
| SCHEMBL3839759 | 0.87 | CRHR1 (0.39) | CRHR1MARS1POLBP2RX7TLR8 | |
| SCHEMBL3843991 | 0.86 | CRHR1 (0.38) | CRHR1CNKSR1IL15IL15RAIL2 | |
| SCHEMBL3844312 | 0.82 | CRHR1 (0.40) | CRHR1MARS1HSD11B1 | |
| SCHEMBL13617371 | 0.82 | CRHR1 (0.37) | CRHR1IL15IL15RAP2RX7 | |
| SCHEMBL6024733 | 0.81 | CRHR1 (0.48) | CRHR1MARS1HSD11B1 | |
| SCHEMBL3364574 | 0.81 | CRHR1 (0.50) | CRHR1HSD11B1 | |
| SCHEMBL3839291 | 0.81 | CRHR1 (0.37) | CRHR1MARS1CNKSR1POLBHSD11B1 | |
| SCHEMBL3839810 | 0.79 | CRHR1 (0.44) | CRHR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007753-B1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2007115966-A1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA1, GABRA2, GABRA3 | CRHR1 96/4885MARS1 4129/4885CNKSR1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.